Natasha Shtrazient,

Dr. Natasha Shtraizent is the Founder, President, and Chief Executive Officer of Frezent Biological Solutions, with over 12 years of experience in cancer research across both academia and industry. She holds a PhD in Developmental & Cell Biology and Biochemistry from Tel Aviv University and Mount Sinai School of Medicine and completed postdoctoral fellowships in cancer research at the Research Foundation, CUNY, and Icahn School of Medicine at Mount Sinai. Dr. Shtraizent’s expertise includes metabolic transformation in cancer, with a focus on mutant p53 proteins and sphingolipid metabolism. Her research has contributed to the development of therapies targeting drug-resistant cancers, particularly through her work on Acid Ceramidase (AC), a key enzyme in cancer metabolism. In addition to her scientific work, Dr. Shtraizent has held leadership roles in translational oncology at Bristol Myers Squibb and has managed numerous NIH-funded projects. She is a member of the American Association for Cancer Research, the New York Academy of Sciences, and other professional organizations.